株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

オリゴヌクレオチド合成の世界市場 - 2024年までの予測:プローブ、リンカー、アダプター、医薬品、試薬、装置

Oligonucleotide Synthesis Market by Product (Probe, Linkers, Adaptor, Drugs, Reagent, Equipment), Type(Custom, Pre Design), Application(PCR, DNA, RNAi, Research, Therapeutic), End User (Hospital, Pharmaceutical, Biotechnology)-Global Forecast to 2024

発行 MarketsandMarkets 商品コード 311580
出版日 ページ情報 英文 231 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.69円で換算しております。
Back to Top
オリゴヌクレオチド合成の世界市場 - 2024年までの予測:プローブ、リンカー、アダプター、医薬品、試薬、装置 Oligonucleotide Synthesis Market by Product (Probe, Linkers, Adaptor, Drugs, Reagent, Equipment), Type(Custom, Pre Design), Application(PCR, DNA, RNAi, Research, Therapeutic), End User (Hospital, Pharmaceutical, Biotechnology)-Global Forecast to 2024
出版日: 2019年04月29日 ページ情報: 英文 231 Pages
概要

世界のオリゴヌクレオチド合成市場は、2019年の43億米ドルから、2024年までに82億米ドルまで拡大すると見られています。市場は、2019年~2024年のCAGR (複合年間成長率) で、13.7%の成長が予測されています。

当レポートでは、世界のオリゴヌクレオチド合成市場について調査分析し、市場概要、産業動向、セグメント別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

311580_4.1 ATTRACTIVE OPPORTUNITIES IN THE OLIGONUCLEOTIDE SYNTHESIS MARKET_FIGURE 10

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • オリゴヌクレオチド合成市場の魅力的な機会
  • 合成オリゴ市場:製品別
  • 合成オリゴ市場:タイプ別
  • アジア太平洋地域 - オリゴヌクレオチド合成市場:研究用途別、国別
  • オリゴヌクレオチド合成市場:治療用途別
  • オリゴヌクレオチド合成市場:エンドユーザー別
  • 地域別スナップショット:オリゴヌクレオチド合成市場

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
    • 市場課題

第6章 オリゴヌクレオチド合成の世界市場:製品別

  • イントロダクション
  • 合成オリゴ
    • 製品別
    • タイプ別
  • 試薬
  • 装置

第7章 オリゴヌクレオチド合成の世界市場:用途別

  • イントロダクション
  • 治療用途
  • 診断用途
  • 研究用途

第8章 オリゴヌクレオチド合成の世界市場:エンドユーザー別

  • イントロダクション
  • 病院
  • 学術研究機関
  • 製薬・バイオテクノロジー企業
  • 臨床検査室

第9章 オリゴヌクレオチド合成の世界市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 競合情勢

  • 概要
  • 市場シェア分析
  • 競合シナリオ
  • 競合リーダーシップマッピング
  • ベンダー比較マトリクス

第11章 企業プロファイル

  • AGILENT TECHNOLOGIES
  • ADTBIO
  • BIOAUTOMATION (LGCが買収)
  • BIO-SYNTHESIS INC.
  • EUROFINS GENOMICS
  • EUROGENTEC
  • GE HEALTHCARE
  • GENSCRIPT
  • GENEDESIGN (味の素の一部)
  • INTEGRATED DNA TECHNOLOGIES (DANAHER CORPORATIONが買収)
  • LGC BIOSEARCH TECHNOLOGIES
  • MERCK KGAA
  • NITTO DENKO AVECIA
  • THERMO FISHER SCIENTIFIC
  • TRILINK BIOTECHNOLOGIES (MARAVAI LIFESCIENCESの一部)

第12章 付録

図表

LIST OF TABLES

  • TABLE 1: FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES
  • TABLE 2: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 3: SYNTHESIZED OLIGOS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 4: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 5: LATE-STAGE OLIGONUCLEOTIDE-BASED THERAPIES
  • TABLE 6: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 7: PRIMERS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 8: PROBES MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 9: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR INTERMEDIATE-SCALE SYNTHESIZED OLIGOS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 10: LARGE-SCALE SYNTHESIZED OLIGOS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 11: LINKERS & ADAPTORS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 12: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 13: PREDESIGNED OLIGOS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 14: CUSTOM OLIGOS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 15: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 16: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 17: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 18: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 19: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 20: ANTISENSE OLIGONUCLEOTIDES IN CLINICAL TRIALS
  • TABLE 21: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DNA & ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 22: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RNAI OLIGONUCLEOTIDE-BASED THERAPIES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 23: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CPG OLIGONUCLEOTIDE-BASED THERAPIES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 24: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 25: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 26: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 27: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR APPLICATIONS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 28: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR QPCR APPLICATIONS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 29: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING APPLICATIONS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 30: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR GENE SYNTHESIS APPLICATIONS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 31: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 32: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 33: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 34: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 35: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 36: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 37: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 38: NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 39: NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 40: NORTH AMERICA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 41: NORTH AMERICA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 42: NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 43: NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 44: NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 45: NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 46: US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 47: US: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 48: US: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 49: US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 50: US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 51: US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 52: CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 53: CANADA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 54: CANADA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 55: CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 56: CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 57: CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 58: EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 59: EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 60: EUROPE: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 61: EUROPE: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 62: EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 63: EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 64: EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 65: EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 66: GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 67: GERMANY: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 68: GERMANY: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 69: GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 70: GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 71: GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 72: FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 73: FRANCE: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 74: FRANCE: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 75: FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 76: FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 77: FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 78: UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 79: UK: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 80: UK: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 81: UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 82: UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 83: UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 84: ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 85: ITALY: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 86: ITALY: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 87: ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 88: ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 89: ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 90: SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 91: SPAIN: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 92: SPAIN: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 93: SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 94: SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 95: SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 96: ROE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 97: ROE: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 98: ROE: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 99: ROE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 100: ROE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 101: ROE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 102: APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 103: APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 104: APAC: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 105: APAC: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 106: APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 107: APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 108: APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 109: APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 110: CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 111: CHINA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 112: CHINA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 113: CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 114: CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 115: CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 116: JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 117: JAPAN: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 118: JAPAN: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 119: JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 120: JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 121: JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 122: INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 123: INDIA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 124: INDIA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 125: INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 126: INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 127: INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 128: ROAPAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 129: ROAPAC: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 130: ROAPAC: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 131: ROAPAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 132: ROAPAC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 133: ROAPAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 134: LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 135: LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 136: LATAM: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 137: LATAM: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 138: LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 139: LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 140: LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 141: LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 142: BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 143: BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 144: BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 145: MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 146: MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 147: MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 148: ROLATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 149: ROLATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 150: ROLATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)
  • TABLE 151: MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 152: MEA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 153: MEA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 154: MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 155: MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 156: MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 157: MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2017-2024 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: DATA TRIANGULATION METHODOLOGY
  • FIGURE 4: SYNTHESIZED OLIGOS DOMINATES THE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019-2024 (USD MILLION)
  • FIGURE 5: OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO RECORD HIGHEST GROWTH, 2019-2024 (USD MILLION)
  • FIGURE 6: PREDESIGNED OLIGOS TO DOMINATE THE OLIGONUCLEOTIDE SYNTHESIS MARKET
  • FIGURE 7: THERAPEUTIC APPLICATIONS HOLD THE LARGEST MARKET SHARE
  • FIGURE 8: HOSPITALS TO GROW AT THE HIGHEST CAGR IN THE END-USER MARKET
  • FIGURE 9: NORTH AMERICA HELD LARGEST SHARE IN 2018 AND TO RECORD HIGHEST CAGR (2019-2024)
  • FIGURE 10: INCREASING USE OF SYNTHESIZED OLIGOS IN MOLECULAR DIAGNOSTICS AND CLINICAL APPLICATIONS ARE DRIVING MARKET GROWTH
  • FIGURE 11: OLIGONUCLEOTIDE-BASED DRUGS TO DOMINATE THE MARKET, 2019-2024 (USD MILLION)
  • FIGURE 12: PREDESIGNED OLIGOS TO COMMAND THE LARGEST SHARE OF THE OLIGONUCLEOTIDE SYNTHESIS MARKET DURING THE FORECAST PERIOD
  • FIGURE 13: PCR HELD THE LARGEST SHARE OF THE ASIA PACIFIC RESEARCH APPLICATIONS MARKET IN 2019
  • FIGURE 14: DNA & ANTISENSE OLIGOS TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 15: HOSPITALS SEGMENT TO WITNESS HIGHEST CAGR, 2019-2024 (USD MILLION)
  • FIGURE 16: THE US TO RECORD THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 17: OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 18: SYNTHESIZED OLIGOS TO RECORD HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 19: THERAPEUTIC APPLICATIONS TO OFFER LUCRATIVE GROWTH OPPORTUNITIES FOR MARKET PLAYERS DURING 2019-2024
  • FIGURE 20: HOSPITALS TO DOMINATE THE OLIGONUCLEOTIDE SYNTHESIS MARKET DURING THE FORECAST PERIOD
  • FIGURE 21: NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
  • FIGURE 22: EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
  • FIGURE 23: APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
  • FIGURE 24: LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
  • FIGURE 25: MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
  • FIGURE 26: KEY DEVELOPMENTS IN THE OLIGONUCLEOTIDE SYNTHESIS MARKET (JAN 2016-JAN 2019)
  • FIGURE 27: MARKET EVOLUTION FRAMEWORK
  • FIGURE 28: GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (FOR RESEARCH AND DIAGNOSTICS), BY KEY PLAYER, 2017
  • FIGURE 29: GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (FOR THERAPEUTICS), BY KEY PLAYER, 2017
  • FIGURE 30: MNM DIVE-VENDOR COMPARISON MATRIX: EXOSOMES MARKET
  • FIGURE 31: AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
  • FIGURE 32: BIOGEN: COMPANY SNAPSHOT
  • FIGURE 33: EUROFINS SCIENTIFIC GROUP: COMPANY SNAPSHOT
  • FIGURE 34: KANEKA: COMPANY SNAPSHOT
  • FIGURE 35: GENERAL ELECTRIC COMPANY (GE): COMPANY SNAPSHOT
  • FIGURE 36: GENSCRIPT: COMPANY SNAPSHOT
  • FIGURE 37: AJINOMOTO: COMPANY SNAPSHOT
  • FIGURE 38: DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 39: MERCK KGAA: COMPANY SNAPSHOT
  • FIGURE 40: NITTO DENKO CORPORATION: COMPANY SNAPSHOT
  • FIGURE 41: SAREPTA THERAPEUTICS: COMPANY SNAPSHOT
  • FIGURE 42: THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
目次
Product Code: BT 2680

"Increasing R&D expenditure by pharmaceutical and biotechnology companies and the rising demand for synthesized oligos in molecular diagnostics & therapeutics are expected to drive the overall growth of the oligonucleotide synthesis market"

The global oligonucleotide synthesis market is projected to reach USD 8.2 billion by 2024 from USD 4.3 billion in 2019, at a CAGR of 13.7% during the forecast period. This market is experiencing significant growth due to the increasing research activities in the pharma and biotech sectors and the rising demand for innovative diagnostic and therapeutic techniques. The increasing applications of oligos in nucleic acid array-based technologies, library preparation, NGS, genomics, nucleic acid-based detection, cell cultures, diagnostics, therapeutics, human identity testing, cloning, genetic engineering, and synthetic biology are also driving the growth of this market.

"Hospitals accounted for the largest share of the oligonucleotide synthesis market, by end user, in 2018"

Based on end user, the oligonucleotide synthesis market is segmented into academic research institutes, pharmaceutical and biotechnology companies, diagnostic laboratories, and hospitals. Hospitals held the largest share of the market in 2018 due to the significant number of inpatient and outpatient visits in hospitals and the requirement of oligonucleotide drugs to cater to the demand of the patient pool suffering from diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and hepatic veno-occlusive disease.

"Synthesized oligos dominated the oligonucleotide synthesis market, by product, in 2018

Based on product, the market is segmented into synthesized oligos, reagents, and equipment. The synthesized oligos segment held the largest share of the market in 2018 and is estimated to grow at the highest CAGR during the forecast period. Growth in this segment is attributed to the increasing applications of synthesized oligos in therapeutics, research, and diagnostics.

"North America to dominate the market during the forecast period"

Geographically, the oligonucleotide synthesis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America was the largest regional market for oligonucleotide synthesis. The North American market is also estimated to grow at the highest CAGR during the forecast period owing to the growing availability of synthesized oligos, along with an increase in R&D funding and activities in the North American region.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type - Tier 1: 35%, Tier 2: 45%, and Tier 3: 20%
  • By Designation - C-level: 45%, D-level: 35%, and Others: 20%
  • By Region - North America: 45%, Europe: 25%, Asia Pacific: 18%, Latin America: 7%, and Middle East and Africa: 3%

List of Companies Profiled in the Report:

  • include Agilent Technologies, Inc. (US)
  • ATDBio Ltd. (UK)
  • Bio-Synthesis, Inc. (US)
  • BioAutomation Corporation (US)
  • LGC Biosearch Technologies (US)
  • Eurofins Genomics (Germany)
  • Eurogentec (Belgium)
  • GeneDesign, Inc. (Japan)
  • GE Healthcare (US)
  • GenScript, Inc. (US)
  • Integrated DNA Technologies (IDT, US)
  • Nitto Denko Avecia, Inc. (US)
  • Sarepta Therapeutics (US)
  • Thermo Fisher Scientific, Inc. (US)
  • TriLink BioTechnologies (US)
  • Sigma-Aldrich Corporation (US) (a part of Merck KGAA)

Reasons to Buy the Report:

This report provides a detailed picture of the global oligonucleotide synthesis market. It aims at estimating the size and future growth potential of the market across different segments, such as product & type, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 SECONDARY DATA
    • 2.2.1 SECONDARY SOURCES
  • 2.3 PRIMARY DATA
    • 2.3.1 KEY DATA FROM PRIMARY SOURCES
  • 2.4 MARKET SIZE ESTIMATION
    • 2.4.1 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
    • 2.4.2 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.6 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 ATTRACTIVE OPPORTUNITIES IN THE OLIGONUCLEOTIDE SYNTHESIS MARKET
  • 4.2 SYNTHESIZED OLIGOS MARKET, BY PRODUCT
  • 4.3 SYNTHESIZED OLIGOS MARKET, BY TYPE
  • 4.4 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY RESEARCH APPLICATION AND COUNTRY (2019)
  • 4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY THERAPEUTIC APPLICATION
  • 4.6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER
  • 4.7 GEOGRAPHIC SNAPSHOT: OLIGONUCLEOTIDE SYNTHESIS MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 MARKET DRIVERS
      • 5.2.1.1 Increasing use of synthesized oligos in molecular diagnostics and clinical applications
      • 5.2.1.2 Increasing government investments and R&D expenditure in pharmaceutical and biotechnology companies
      • 5.2.1.3 Rise in venture capital investments
    • 5.2.2 MARKET RESTRAINTS
      • 5.2.2.1 Price erosion of synthesized oligos
      • 5.2.2.2 Lack of a unified set of regulations for therapeutic oligos
    • 5.2.3 MARKET OPPORTUNITIES
      • 5.2.3.1 Emerging Asian markets
    • 5.2.4 MARKET CHALLENGES
      • 5.2.4.1 Large-scale synthesis of oligos
      • 5.2.4.2 Delivery of oligonucleotide drugs to specific targets

6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 SYNTHESIZED OLIGOS
    • 6.2.1 SYNTHESIZED OLIGOS MARKET, BY PRODUCT
      • 6.2.1.1 Oligonucleotide-based drugs
        • 6.2.1.1.1 Oligonucleotide-based drugs dominate the synthesized oligos market, by product
      • 6.2.1.2 Primers
        • 6.2.1.2.1 Growing research activity drives the market for primers
      • 6.2.1.3 Probes
        • 6.2.1.3.1 Probes are designed to detect various infectious agents
      • 6.2.1.4 Intermediate-scale synthesized oligos
        • 6.2.1.4.1 The increasing demand for synthesized oligos and innovations in manufacturing techniques drives the market.
      • 6.2.1.5 Large-scale synthesized oligos
        • 6.2.1.5.1 Increasing demand for large quantities of modified and unmodified oligos to drive the market
      • 6.2.1.6 Linkers & Adaptors
        • 6.2.1.6.1 Linkers are used to add restriction sites in DNA
    • 6.2.2 SYNTHESIZED OLIGOS MARKET, BY TYPE
      • 6.2.2.1 Predesigned oligos
        • 6.2.2.1.1 Predesigned oligos dominate the oligonucleotide synthesis market, by type
      • 6.2.2.2 Custom oligos
        • 6.2.2.2.1 Increasing number of clinical and pre-clinical research to drive the market for custom oligos
  • 6.3 REAGENTS
  • 6.4 EQUIPMENT

7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 THERAPEUTIC APPLICATIONS
    • 7.2.1 DNA & ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES
      • 7.2.1.1 DNA & antisense oligos form the largest segment in the therapeutic applications market
    • 7.2.2 RNAI OLIGONUCLEOTIDE-BASED THERAPIES
      • 7.2.2.1 Significant initiatives by pharmaceutical and biotechnology companies to drive the market for RNAi oligonucleotide-based therapies
    • 7.2.3 CPG OLIGONUCLEOTIDE-BASED THERAPIES
      • 7.2.3.1 This market segment is in the initial stage, and significant growth might be observed during the forecast period
  • 7.3 DIAGNOSTIC APPLICATIONS
  • 7.4 RESEARCH APPLICATIONS
    • 7.4.1 PCR
      • 7.4.1.1 Increasing use of PCR in research to drive market growth
    • 7.4.2 QPCR
      • 7.4.2.1 Its cost-effectiveness, concurrent monitoring of expression levels of multiple genetic messages in real time, and high sensitivity make QPCR a vital tool for quantification of nucleic acids
    • 7.4.3 SEQUENCING
      • 7.4.3.1 Advancements in sequencing technologies and low cost to drive the market for sequencing applications
    • 7.4.4 GENE SYNTHESIS
      • 7.4.4.1 Increasing applications of gene synthesis and low cost to drive the market for this application segment
    • 7.4.5 OTHER RESEARCH APPLICATIONS

8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER

  • 8.1 INTRODUCTION
  • 8.2 HOSPITALS
    • 8.2.1 HOSPITALS ARE THE LARGEST END USERS OF OLIGOS DUE TO THE SIGNIFICANT NUMBER OF INPATIENT AND OUTPATIENT VISITS
  • 8.3 ACADEMIC RESEARCH INSTITUTES
    • 8.3.1 ACADEMIC RESEARCHERS PRIMARILY USE OLIGOS FOR GENETIC ENGINEERING, PCR ACTIVITIES, AND HIGH-THROUGHPUT SEQUENCING-A MAJOR FACTOR DRIVING MARKET GROWTH
  • 8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 8.4.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO DRIVE THE DEMAND FOR OLIGONUCLEOTIDE SYNTHESIS AMONG THESE END USERS

  • 8.5 DIAGNOSTIC LABORATORIES
    • 8.5.1 DIAGNOSTIC LABORATORIES REGISTER HIGH GROWTH IN THE OLIGONUCLEOTIDE SYNTHESIS MARKET DUE TO THE INCREASING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS

9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    • 9.2.1 US
      • 9.2.1.1 Government initiatives and strategic developments by market players to drive market growth in the country
    • 9.2.2 CANADA
      • 9.2.2.1 Growing initiatives and funding in synthetic biology and genomics to drive the market in the country
  • 9.3 EUROPE
    • 9.3.1 GERMANY
      • 9.3.1.1 Presence of a large number of academic research institutes to support market growth
    • 9.3.2 FRANCE
      • 9.3.2.1 Government initiatives to boost R&D activities in the country
    • 9.3.3 UK
      • 9.3.3.1 Growth in the life science industry to drive the market for oligonucleotides synthesis in the UK
    • 9.3.4 ITALY
      • 9.3.4.1 Increasing research activities to drive the market for oligonucleotides synthesis in Italy
    • 9.3.5 SPAIN
      • 9.3.5.1 Government initiatives to drive the market for oligonucleotide synthesis
    • 9.3.6 ROE
  • 9.4 ASIA PACIFIC
    • 9.4.1 CHINA
      • 9.4.1.1 Government initiatives to strengthen the biotechnology industry in China
    • 9.4.2 JAPAN
      • 9.4.2.1 Increasing awareness through conferences and workshops to drive the market in the country
    • 9.4.3 INDIA
      • 9.4.3.1 Government initiatives to promote synthetic biology to drive the market in the country
    • 9.4.4 ROAPAC
  • 9.5 LATIN AMERICA
    • 9.5.1 BRAZIL
      • 9.5.1.1 Development in genomics to aid market growth in Brazil

    • 9.5.2 MEXICO
      • 9.5.2.1 Increasing awareness about advancements in oligonucleotides to drive the market
    • 9.5.3 ROLATAM
  • 9.6 MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 MARKET SHARE ANALYSIS
  • 10.3 COMPETITIVE SCENARIO
    • 10.3.1 PARTNERSHIPS, AGREEMENTS, CONTRACTS, AND COLLABORATIONS
    • 10.3.2 PRODUCT LAUNCHES, UPGRADES, AND APPROVALS
    • 10.3.3 EXPANSIONS
    • 10.3.4 ACQUISITIONS
  • 10.4 COMPETITIVE LEADERSHIP MAPPING (2017)
    • 10.4.1 VANGUARDS
    • 10.4.2 INNOVATORS
    • 10.4.3 DYNAMIC PLAYERS
    • 10.4.4 EMERGING PLAYERS
  • 10.5 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2018)
    • 10.5.1 PROGRESSIVE COMPANIES
    • 10.5.2 STARTING BLOCKS
    • 10.5.3 RESPONSIVE COMPANIES
    • 10.5.4 DYNAMIC COMPANIES
  • 10.6 MNM DIVE-VENDOR COMPARISON MATRIX FOR START-UPS: OLIGONUCLEOTIDE SYNTHESIS MARKET

11 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MnM View)*

  • 11.1 AGILENT TECHNOLOGIES
  • 11.2 ADTBIO
  • 11.3 BIOAUTOMATION (ACQUIRED BY LGC)
  • 11.4 BIO-SYNTHESIS INC.
  • 11.5 BIOGEN
  • 11.6 EUROFINS GENOMICS
  • 11.7 EUROGENTEC
  • 11.8 GE HEALTHCARE
  • 11.9 GENSCRIPT
  • 11.10 GENEDESIGN (PART OF AJINOMOTO)
  • 11.11 INTEGRATED DNA TECHNOLOGIES (ACQUIRED BY DANAHER CORPORATION)
  • 11.12 LGC BIOSEARCH TECHNOLOGIES
  • 11.13 MERCK KGAA
  • 11.14 NITTO DENKO AVECIA
  • 11.15 SAREPTA THERAPEUTICS
  • 11.16 THERMO FISHER SCIENTIFIC
  • 11.17 TRILINK BIOTECHNOLOGIES (PART OF MARAVAI LIFESCIENCES)

Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 12.2 DISCUSSION GUIDE
  • 12.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.4 AVAILABLE CUSTOMIZATIONS
  • 12.5 RELATED REPORTS
  • 12.6 AUTHOR DETAILS
Back to Top